{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-010821","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2022-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.059730+00:00","generated_at":"2026-06-24T12:02:41.823756+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Capricor dosed first patient in Phase 3 HOPE-3 trial of CAP-1002 for Duchenne MD","bullets":["First patient dosed in randomized, double-blind, placebo-controlled HOPE-3 trial enrolling ~70 patients in U.S.","CAP-1002 is a cell therapy for late-stage Duchenne muscular dystrophy; Phase 2 data showed up to 70% slowing of upper limb function loss.","Primary endpoint is Performance of the Upper Limb 2.0; RMAT and Orphan Drug designations support regulatory pathway.","Nippon Shinyaku partnership provides funding and commercialization rights in U.S.; Capricor holds rest-of-world rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-010821","json":"https://secwatch.observer/filing/0001558370-22-010821.json","markdown":"https://secwatch.observer/filing/0001558370-22-010821.md","text":"https://secwatch.observer/filing/0001558370-22-010821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837022010821/0001558370-22-010821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837022010821/capr-20220719x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T12:02:41.823756+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}